Taken together, these results show differences in the kinetics of CD4 + and CD8 + T cell proliferation and trafficking in response to ICB treatment and suggest distinct underlying mechanisms to explain the impact of α-PD1 and α-CTLA4 treatment on immunologically “cold” breast tumors. The gene discussed is CTLA4; the disease is breast neoplasm.